stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Net income
Beam Therapeutics Inc.'s net income for fiscal 2025 was −$80.0M, compared with −$376.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$108.4M. Over the past ten years it has ranged from −$376.7M (fiscal 2024) to $0.00 (fiscal 2017); the current reading is higher than 78% of that period. Beam Therapeutics Inc. ranks 438th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$80.0M | — |
| FY2024 | −$376.7M | — |
| FY2023 | −$132.5M | — |
| FY2022 | −$289.1M | — |
| FY2021 | −$370.6M | — |
| FY2020 | −$194.6M | — |
| FY2019 | −$78.3M | — |
| FY2018 | −$116.7M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$134.4M | — |
| Jun 2026 | −$122.7M | — |
| Mar 2026 | −$94.3M | — |
| Dec 2025 | $243.0M | — |
| 28 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| BEAM Beam Therapeutics Inc. | −$108.4M |
| XNCR Xencor, Inc. compare | −$163.3M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| RCUS Arcus Biosciences, Inc. compare | −$453.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BEAM
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement